Preclinical mechanistic study
NMN Maintains Intestinal Homeostasis by Regulating the Gut Microbiota
Pan Huang, Anqi Jiang, Xuxin Wang, Yan Zhou, Weihong Tang, Caifang Ren, Xin Qian, Zhengrong Zhou, Aihua Gong
Frontiers in Nutrition · 2021 · 8:714604
Study at a glance
- Design
- Preclinical long-term mouse feeding study with 16S rDNA microbiome profiling, fecal metabolomics and intestinal-barrier assays
- Population or model
- C57BL/6J mice
- Sample size
- Multiple dietary NMN groups; see publication for group sizes
- Intervention
- Different concentrations of NMN administered long term in drinking water/feed regimen
- Publication type
- Preclinical animal study
- Evidence class
- preclinical-mechanistic
- Research area
- Gut microbiome and intestinal barrier
- Trial registration
- Not applicable.
Study endpoints
- Gut microbiota diversity and composition
- Fecal metabolites and bile acids
- Goblet cells and mucus thickness
- Tight-junction proteins
- Intestinal mucosal permeability
Plain-language summary
Key findings
Limitations
Funding and transparency
Funding
Funded by the Postdoctoral Science Foundation of China (2020M681514), Postdoctoral Science Foundation of Jiangsu Province (2020Z346 and 2020Z400), and Foundation of Natural Science Research in Higher Education of Jiangsu Province (20KJB310005).
Competing interests
The authors declared that the research was conducted in the absence of commercial or financial relationships that could be construed as a potential conflict of interest.
HealthspanX observation
Microbiome shifts should not be labeled simply beneficial or harmful without human functional evidence.
Interpretive weight
Mechanistic context
Long-term mouse study links NMN with microbiome and intestinal-barrier changes, but microbiome composition and barrier findings are preclinical and not evidence of human gut benefit.
This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.